Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daylight vs Conventional ALA-PDT for Actinic Keratosis
NCT03322293Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- Dec 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of aminolevulinic acid 10% gel in actinic keratosis (AK) (3 arms), sponsored by University of California, San Francisco. Primary endpoint: Change in Treatment Symptoms at 12 weeks. Started Dec 2017; status: completed.
02
Drugs
aminolevulinic acid 10% gel
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT03322293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03322293.